Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
To observe the effectiveness of SHR-1210 (Camrelizumab) combined with apatinib in the
treatment of unresectable sarcoma patients with chemotherapy failure. The main observations
were progression-free survival (PFS) and progression-free control rate (PFR), followed by
objective response rate (ORR) (CR+PR), disease control rate (DCR) (CR+PR+SD), and overall
survival (OS).
To observe the safety of SHR-1210 (Camrelizumab) combined with apatinib in the treatment of
sarcoma
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital